Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Current Assets (2017 - 2025)

Historic Current Assets for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $857.0 million.

  • Arcus Biosciences' Current Assets fell 2395.74% to $857.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $857.0 million, marking a year-over-year decrease of 2395.74%. This contributed to the annual value of $1.0 billion for FY2024, which is 2226.23% up from last year.
  • Arcus Biosciences' Current Assets amounted to $857.0 million in Q3 2025, which was down 2395.74% from $946.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Current Assets registered a high of $1.3 billion during Q1 2022, and its lowest value of $545.3 million during Q3 2021.
  • Over the past 5 years, Arcus Biosciences' median Current Assets value was $1.0 billion (recorded in 2024), while the average stood at $991.2 million.
  • Within the past 5 years, the most significant YoY rise in Arcus Biosciences' Current Assets was 40648.85% (2021), while the steepest drop was 3159.95% (2021).
  • Over the past 5 years, Arcus Biosciences' Current Assets (Quarter) stood at $1.3 billion in 2021, then dropped by 15.45% to $1.1 billion in 2022, then dropped by 22.12% to $831.0 million in 2023, then grew by 22.26% to $1.0 billion in 2024, then decreased by 15.65% to $857.0 million in 2025.
  • Its Current Assets was $857.0 million in Q3 2025, compared to $946.0 million in Q2 2025 and $1.0 billion in Q1 2025.